Burcon Nutrascience Corporation (TSX: BU) is making significant progress at its Galesburg facility, transitioning from commissioning to early utilization as customer volumes grow. According to a report from Stonegate Capital Partners released Thursday, the company is beginning to benefit from better fixed-cost absorption as it ramps up production across its pea, canola, and fava protein lines.
During fiscal year 2026, Burcon completed commissioning and launched commercial production for its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines. Revenue increased sequentially to $0.83 million in the fourth quarter of 2026, up from $0.74 million in the third quarter. Management reported that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity, indicating strong momentum.
The company also achieved a new production record, with daily output roughly 60% above January to March levels. Stonegate Capital Partners noted that as volume builds, the margin opportunity should come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone. This suggests that operational efficiencies are driving profitability improvements.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales. These developments underscore Burcon's growing presence in the plant-based protein market.
Stonegate Capital Partners, a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies, issued the update. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services for public and private companies. The report highlights Burcon's strategic progress as it moves toward commercial viability.
